The participation of BCL-xL in resistance to treatment has been evidenced in multiple myeloma cells that co-express Bcl-2 and BCL-xL, which were resistant to treatment with venetoclax but were sensitive to treatment with the specific inhibitor of BCL-xL A-1155463. This evidence concerns the gene BCL2L1 and AL amyloidosis.